



INNSBRUCK, AUSTRIA 1969 - 1971




LONDON, GREAT BRITAIN 1982 - 1983




HEIDELBERG, GERMANY 1989



SUDBURY, CANADA 1990 - 1992



SAN DIEGO, CALIFORNIA 1992 - 1998



ADVANCES IN STEM CELL TRANSPLANTATION AND IMMUNE THERAPY
30 years of blood stem cell transplantation and 1000th allogeneic transplantation in Heidelberg

SYMPOSIUM honouring the 65th birthday of Prof. Anthony D. Ho

INVITATION

DEAR COLLEAGUES AND FRIENDS,

It is now 30 years since the first autologous blood stem cell transplantation was performed in Heidelberg. Being one of the first PBSCTs world-wide, this pioneer achievement was the cornerstone for the rapidly evolving Heidelberg stem cell transplantation activity. With more than 200 autologous and 100 allogeneic transplants per year, the Heidelberg stem cell transplantation program is now the largest in Germany with particular focus on lymphoproliferative diseases and myeloma.

To celebrate this anniversary and the recent performance of the 1000th allogeneic transplantation in Heidelberg, we would like to welcome you to our symposium highlighting recent advances in stem cell transplantation and immune therapy. We are happy that we can dedicate this conference to Professor Anthony D. Ho on the occasion of his 65th birthday. Professor Ho was not only personally involved in the very first stem cell transplantation and a founding member of the Heidelberg transplant program, but has also largely contributed to its outstanding development and accounted for the successful expansion of its allogeneic part.

We are proud and grateful that we can present you a unique faculty of international experts in stem cell transplantation and immune therapy (most of them with Heidelbergian roots!) and are looking forward to two days of exciting science.



Peter Dreger

Alwin Krämer

Hanns-Martin Lorenz

on behalf of the Organizing Committee

Organizing Committee

Peter Dreger, Gerlinde Egerer, Emmie Ho-Tsui, Alwin Krämer, Hanns-Martin Lorenz, Barbara Ludwig, Johann-Wilhelm Schmier, Michael Schmitt, Christiane Wickenhöfer, Patrick Wuchter

FRIDAY, SEPTEMBER 13, 2013

12:30 – 14:00
14:00 – 14:30

**WELCOME RECEPTION BY PROF. DR. ANTHONY D. HO
OPENING AND WELCOME TO THE SYMPOSIUM**
Staatsministerin Maria Böhmer, Beauftragte der Bundesregierung für Migration, Flüchtlinge und Integration, Bundeskanzleramt, Berlin
Eckart Würzner, Mayor, City of Heidelberg
Georg F. Hoffmann, Vice-Dean, Faculty of Medicine, University of Heidelberg
Hugo Katus, Speaker of the Board, Department of Medicine, University Hospital Heidelberg
Harald zur Hausen, Nobel Prize Laureate 2008, Professor emeritus, German Cancer Research Center, Heidelberg

14:30 – 15:15

KEY NOTE SPEECH
Chairperson: Gerhard Ehninger (Dresden)
Hans-Jochem Kolb, Munich
The potentials and perspectives of graft-versus-leukemia activities
Coffee Break

15:15 – 15:45

SESSION I

PERSPECTIVES OF TARGETED THERAPY
Chairpersons: Kai Neben (Baden-Baden), Martin Görner (Bielefeld)
Michael Andreeff, Houston
Biology and targeting of the leukemia stem cell niche
Hartmut Goldschmidt, Heidelberg
Heidelberg experience in multiple myeloma during the last two decades
Bart Barlogie, Little Rock
The curability of multiple myeloma: current status and path for the future

15:45 – 16:15

16:15 – 16:45

16:45 – 17:15

SATURDAY, SEPTEMBER 14, 2013

SESSION II

08:30 – 09:00

09:00 – 09:30

09:30 – 10:00

10:00 – 10:30

SESSION III

10:30 – 11:00

11:00 – 11:30

11:30 – 12:00

12:00 – 12:30

12:30 – 13:15

TRANSPLANTATION AND ACUTE LEUKEMIA
Chairpersons: Uwe Martens (Heilbronn), Stefan Frühauf (Osnabrück)
Sabine Scherer, Heidelberg
Heidelberg Stem Cell Register: 10 years serving mankind
Ted Ball, San Diego
AML: The place of autologous stem cell transplantation in 2013
Gerhard Ehninger, Dresden
25 years of AML therapy from mitoxantrone to arsenic trioxide – how far did we get?
Coffee Break

LYMPHOMA AND STEM CELL BIOLOGY
Chairpersons: Peter Dreger (Heidelberg), Antonio Pezzutto (Berlin)
Michael Pfreundschuh, Homburg
Dose intensity in aggressive B cell lymphoma – must or myth?
Rainer Haas, Düsseldorf
Autologous stem cell transplantation in follicular and mantle cell lymphoma – still indicated in the rituximab era?
Bernd Dörken, Berlin
Reprogramming neoplastic B cells – implications for cancer stem cell biology
Wolfgang Wagner, Aachen
Forever young: DNA methylation changes in long-term culture and aging
Farewell Lunch, Foyer, Lecture Hall

WHERE? LECTURE HALL AND FOYER, MEDIZINISCHE UNIVERSITÄTSKLINIK, IM NEUENHEIMER FELD 410

REGISTRATION

SURNAME

FIRST NAME

ACADEMIC TITLE

INSTITUTION

EMAIL

PLEASE FAX TO
+49-6221-56-6550

PLATINUM SPONSORS | 5000,00 EURO |



GOLD SPONSORS | 3000,00 EURO |



SILVER SPONSORS | 1500,00 EURO |



BRONZE SPONSORS | 1000,00 EURO |

